Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.

Voss, Tiffini; Li, Jerry; Cummings, Jeffrey; Farlow, Martin; Assaid, Christopher; Froman, Samar; Leibensperger, Heather; Snow-Adami, Linda; McMahon, Kerry Budd; Egan, Michael; Michelson, David

Voss, Tiffini; Li, Jerry; Cummings, Jeffrey; Farlow, Martin; Assaid, Christopher; Froman, Samar; Leibensperger, Heather; Snow-Adami, Linda; McMahon, Kerry Budd; Egan, Michael; Michelson, David.

Afiliação

Voss T; Merck & Co. Inc., Kenilworth, NJ, USA.
Li J; Merck & Co. Inc., Kenilworth, NJ, USA.
Cummings J; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Farlow M; Indiana University School of Medicine, Indianapolis, IN, USA.
Assaid C; Merck & Co. Inc., Kenilworth, NJ, USA.
Froman S; Merck & Co. Inc., Kenilworth, NJ, USA.
Leibensperger H; Merck & Co. Inc., Kenilworth, NJ, USA.
Snow-Adami L; Merck & Co. Inc., Kenilworth, NJ, USA.
McMahon KB; Merck & Co. Inc., Kenilworth, NJ, USA.
Egan M; Merck & Co. Inc., Kenilworth, NJ, USA.
Michelson D; Merck & Co. Inc., Kenilworth, NJ, USA.

Alzheimers Dement (N Y) ; 4: 173-181, 2018.

Article em En | MEDLINE | ID: mdl-29955661

Palavras-chave

Allosteric modulator; Alzheimer's disease; Cholinergic; Clinical trial; MK-7622; Muscarinic

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Alzheimers Dement (N Y) Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google